Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001055947-10-000006
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-02-09 12:00:00
Reporting Period:
2010-02-05
Filing Date:
2010-02-09
Accepted Time:
2010-02-09 17:16:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1441848 Facet Biotech Corp FACT Pharmaceutical Preparations (2834) 263070657
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
918923 P L Fund Value Biotechnology 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1055947 P/il L Partners Bvf 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No Yes No
1056807 Bvf Inc/il 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No Yes No
1102444 Biotechnology Value Fund Ii Lp 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1132245 Bvf Investments Llc 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1233840 N Mark Lampert 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-02-05 1,000 $15.00 3,901,870 No 4 P Direct
Common Stock Acquisiton 2010-02-05 1,000 $15.00 3,902,870 No 4 P Direct
Common Stock Acquisiton 2010-02-05 3,000 $15.00 3,905,870 No 4 P Direct
Common Stock Acquisiton 2010-02-08 3,200 $15.37 3,909,070 No 4 P Direct
Common Stock Acquisiton 2010-02-08 3,000 $15.37 3,912,070 No 4 P Direct
Common Stock Acquisiton 2010-02-08 9,000 $15.37 3,921,070 No 4 P Direct
Common Stock Acquisiton 2010-02-09 5,000 $15.69 3,926,070 No 4 P Direct
Common Stock Acquisiton 2010-02-09 3,000 $15.69 3,929,070 No 4 P Direct
Common Stock Acquisiton 2010-02-09 11,000 $15.69 3,940,070 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,940,070 Indirect General partner and manager of entities with direct ownership.
Common Stock 3,940,070 Indirect General Partner of entity with indirect ownership.
Common Stock 3,940,070 Indirect Sole shareholder and sole director of entity with indirect ownership.
Footnotes
  1. Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request.
  2. Shares directly beneficially owned by Biotechnology Value Fund, L.P. ("BVF")
  3. Shares directly beneficially owned by Biotechnology Value Fund II, L.P. ("BVF II")
  4. The shares of Common Stock are directly beneficially owned by BVF Investments, LLC ("BVFLLC"), a Delaware limited liability company. Pursuant to the operating agreement of BVFLLC, BVF Partners, L.P., a Delaware limited partnership ("Partners") is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVFLLC, in the shares of Common Stock and other securities and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
  5. The shares of Common Stock are indirectly beneficially owned by Partners. Partners is the general partner of BVF and BVF II and is the manager of BVFLLC.
  6. The shares of Common Stock are indirectly beneficially owned by BVF Inc., a Delaware corporation ("BVF Inc."). BVF Inc. is the general partner of Partners.
  7. Mark N. Lampert is the sole shareholder, sole director, and an officer of BVF Inc.